**Supplementary Table 3.** Binomial logistic regression analysis for *TERT* genetic alterations in HCC patients

| Factors | All | | | Young (age ≤60 yr) | | | Old (age >60 yr) | | |
|---|---|---|---|---|---|---|---|---|---|
| | OR | 95% CI | *P*-value | OR | 95% CI | *P*-value | OR | 95% CI | *P*-value |
| Sex | | | | | | | | | |
| Female | Reference | - | - | Reference | - | - | Reference | - | - |
| Male | 4.267 | 1.980–9.198 | <0.001 | 10.145 | 3.634–28.324 | <0.001 | 0.667 | 0.113–3.919 | 0.654 |
| Age | 1.045 | 1.004–1.087 | 0.030 | 1.041 | 0.986–1.099 | 0.147 | 1.001 | 0.844–1.187 | 0.993 |
| HBeAg | | | | | | | | | |
| Negative | Reference | - | - | Reference | - | - | Reference | – | – |
| Positive | 1.799 | 0.700–4.625 | 0.223 | 1.829 | 0.641–5.224 | 0.259 | 2.100 | 0.214–20.640 | 0.525 |
| HBsAg | | | | | | | | | |
| ≤100 IU/mL | Reference | - | - | Reference | - | - | Reference | - | - |
| >100 IU/mL | 0.763 | 0.260–2.238 | 0.622 | 0.836 | 0.214–3.272 | 0.797 | 0.667 | 0.099–4.478 | 0.677 |
| HBV DNA | | | | | | | | | |
| ≤100 IU/mL | Reference | - | - | Reference | - | - | Reference | - | - |
| >100 IU/mL | 0.851 | 0.349–2.074 | 0.723 | 0.871 | 0.311–2.440 | 0.793 | 0.833 | 0.137–5.077 | 0.843 |
| AST | | | | | | | | | |
| ≤40 U/L | Reference | - | - | Reference | - | - | Reference | - | - |
| >40 U/L | 0.844 | 0.395–1.803 | 0.662 | 1.275 | 0.532–3.054 | 0.586 | 0.300 | 0.057–1.577 | 0.155 |
| ALT | | | | | | | | | |
| ≤40 U/L | Reference | - | - | Reference | - | - | Reference | - | - |
| >40 U/L | 0.847 | 0.392–1.829 | 0.673 | 1.168 | 0.485–2.812 | 0.729 | 0.417 | 0.077–2.253 | 0.309 |
| Total bilirubin | | | | | | | | | |
| ≤1 mg/dL | Reference | - | - | Reference | - | - | Reference | - | - |
| >1 mg/dL | 1.234 | 0.598–2.546 | 0.569 | 1.697 | 0.741–3.886 | 0.211 | 0.364 | 0.073–1.810 | 0.217 |
| Albumin | | | | | | | | | |
| ≤3.5 g/dL | Reference | - | - | Reference | - | - | Reference | - | - |
| >3.5 g/dL | 0.496 | 0.216–1.137 | 0.098 | 0.466 | 0.189–1.153 | 0.098 | 0.469 | 0.049–4.497 | 0.512 |
| Prothrombin time | | | | | | | | | |
| ≤1 INR | Reference | - | - | Reference | - | - | Reference | - | - |
| >1 INR | 0.509 | 0.178–1.452 | 0.207 | 0.561 | 0.169–1.865 | 0.346 | 0.469 | 0.049–4.497 | 0.512 |
| Liver cirrhosis | | | | | | | | | |
| No | Reference | - | - | Reference | - | - | Reference | - | - |
| Yes | 0.882 | 0.450–1.730 | 0.716 | 0.800 | 0.376–1.702 | 0.562 | 1.308 | 0.274–6.240 | 0.737 |

https://doi.org/10.3350/cmh.2024.0545
http://www.e-cmh.org

https://doi.org/10.3350/cmh.2024.0545


**Supplementary Table 3.** Continued

| Factors | All | | | Young (age ≤60 yr) | | | Old (age >60 yr) | | |
|---|---|---|---|---|---|---|---|---|---|
| | OR | 95% CI | *P*-value | OR | 95% CI | *P*-value | OR | 95% CI | *P*-value |
| Family history of HCC | | | | | | | | | |
| No | Reference | - | - | Reference | - | - | Reference | - | - |
| Yes | 0.520 | 0.162–1.668 | 0.272 | 0.728 | 0.210–2.520 | 0.616 | 0.000 | 0.000– | 1.000 |
| Antiviral therapy | | | | | | | | | |
| No | Reference | - | - | Reference | - | - | Reference | - | - |
| Yes | 1.177 | 0.601–2.306 | 0.635 | 1.212 | 0.573–2.564 | 0.615 | 1.111 | 0.223–5.542 | 0.898 |
| Child–Pugh class | | | | | | | | | |
| A | Reference | - | - | Reference | - | - | Reference | - | - |
| B/C | 1.201 | 0.464–3.109 | 0.706 | 2.027 | 0.686–5.987 | 0.201 | 0.103 | 0.008–1.333 | 0.082 |
| AFP | | | | | | | | | |
| ≤40 ng/mL | Reference | - | - | Reference | - | - | Reference | - | - |
| >40 ng/mL | 0.736 | 0.370–1.464 | 0.382 | 0.726 | 0.340–1.552 | 0.409 | 0.813 | 0.150–4.404 | 0.810 |
| Tumor size | | | | | | | | | |
| ≤5 cm | Reference | - | - | Reference | - | - | Reference | - | - |
| >5 cm | 1.111 | 0.554–2.228 | 0.767 | 1.366 | 0.635–2.939 | 0.425 | 0.750 | 0.120–4.691 | 0.758 |
| Tumor number | | | | | | | | | |
| Single | Reference | - | - | Reference | - | - | Reference | - | - |
| Multiple | 1.156 | 0.577–2.316 | 0.682 | 1.376 | 0.644–2.941 | 0.409 | 0.462 | 0.068–3.134 | 0.429 |
| mUICC stage | | | | | | | | | |
| I/II | Reference | - | - | Reference | - | - | Reference | - | - |
| III | 1.037 | 0.452–2.378 | 0.932 | 1.571 | 0.630–3.920 | 0.333 | 0.462 | 0.036–5.966 | 0.554 |
| IV | 1.320 | 0.574–3.038 | 0.514 | 2.043 | 0.815–5.119 | 0.127 | 0.462 | 0.036–5.966 | 0.554 |
| BCLC stage | | | | | | | | | |
| 0/A | Reference | - | - | Reference | - | - | Reference | - | - |
| B | 0.915 | 0.416–2.014 | 0.825 | 1.267 | 0.513–3.132 | 0.608 | 0.424 | 0.076–2.373 | 0.329 |
| C | 1.203 | 0.515–2.812 | 0.669 | 1.883 | 0.750–4.727 | 0.178 | 0.182 | 0.009–3.542 | 0.261 |

AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate transaminase; BCLC, Barcelona Clinic for Liver Cancer; CI, confidence interval; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; INR, international normalized ratio; mUICC, modified Union for International Cancer Control; OR, odds ratio; TERT, telomerase reverse transcriptase; yr, years.